This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Integrilin

Merck & Co., Inc.

Drug Names(s): eptifibatide

Description: Integrilin is currently indicated for the treatment of patients with acute coronary syndromes (ACS) as part of both medically-managed and percutaneous coronary intervention (PCI)-managed revascularization strategies. Its anti-platelet effects, combined with the clot-lysing effects of a thrombolytic such as tenecteplase, may provide a certain proportion of ACS patients with clinical benefits greater than those offered by either as monotherapy. The specific patient populations for which benefit exceeds, especially bleeding, risk remain to be seen for the most part.

Integrilin competes with two other marketed gpIIb/IIIa inhibitors -- Merck's Aggrastat and Eli Lilly's ReoPro.

Deal Structure: In January 2001, COR and Schering-Plough partnered with Genentech to co-promote Integrilin with Genentech's TNKase and Activase in the United States.

Millennium acquired rights to Integrilin through its acquisiton of COR in December 2001.

In July 2005, Schering-Plough and Millennium agreed to restructure their collaboration for INTEGRILIN. Under the new relationship, Schering-Plough will acquire exclusive development and commercialization rights to INTEGRILIN in the U.S. Schering-Plough and Millennium have been co-promoting INTEGRILIN in the United States and sharing profits since 2002.

Under the terms of the agreement, Schering-Plough will pay to Millennium an upfront payment of $35.5 million and royalties over the U.S. lifespan of INTEGRILIN. In 2006 and 2007, minimum royalty payments for each year are set at $85 million, with some extraordinary conditions that could reduce these minimums. In addition, Schering-Plough will pay to Millennium approximately $45-50 million for...See full deal structure in Biomedtracker

Partners: Takeda Pharmaceutical Company Ltd GlaxoSmithKline plc


Integrilin News

Pink Sheet Integrilin


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug